Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Perioperative management of antithrombotic drugs in the real world: Study of the impact of not following the consensus document.

Revista espanola de anestesiologia y reanimacion·2026

Same author

Strong Coupling and Dark Modes in the Motion of a Pair of Levitated Nanoparticles.

Physical review letters·2025

Same author

High purity two-dimensional levitated mechanical oscillator.

Nature communications·2025

Same author

Spectral Analysis of Quantum Field Fluctuations in a Strongly Coupled Optomechanical System.

Physical review letters·2023

Same author

Impact of Diabetes Mellitus and Frailty on Long-Term Outcomes in Elderly Patients with Acute Coronary Syndromes.

The journal of nutrition, health & aging·2020

Same author

Efficacy of teriparatide compared with risedronate on FRAX<sup>®</sup>-defined major osteoporotic fractures: results of the VERO clinical trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020

Search research articles

Related Experiment Video

Updated: May 24, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

New perspectives in antiplatelet therapy.

A Tello-Montoliu¹, E Jover, J Rivera

¹Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Ctra Madrid-Cartagena Murcia, 30120, Spain.

Current Medicinal Chemistry

|February 17, 2012

Summary

Novel antiplatelet agents are being developed to improve treatment for arterial thrombosis and atherothrombotic disease, addressing limitations of current therapies like recurrent ischemic events and bleeding complications.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Experiment Videos

Last Updated: May 24, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Area of Science:

Cardiovascular Medicine
Pharmacology
Hematology

Background:

Platelet activation is crucial in vascular injury and atherothrombotic disease, leading to thrombus formation.
Existing antiplatelet drugs targeting cyclooxygenase-1 (COX-1), integrin αIIbβ3, and P2Y(12) receptor have limitations, including recurrent ischemic events and bleeding.
Understanding platelet activation mechanisms drives the development of novel antiplatelet therapies.

Purpose of the Study:

To review novel antiplatelet agents targeting various pathways of platelet activation.
To summarize the mechanisms of action and current clinical evaluation of these emerging drugs.
To highlight advancements in antiplatelet therapy for arterial thrombosis.

Main Methods:

Review of current literature on novel antiplatelet agents.
Summary of mechanisms of action for drugs targeting P2Y(12) receptor, PAR-1, integrin αIIbβ3, thromboxane receptor (TP), phosphodiesterases, glycoprotein VI, and intraplatelet signaling.
Analysis of ongoing clinical evaluations of these agents.

Main Results:

Several novel antiplatelet agents are under development, including new P2Y(12) inhibitors, PAR-1 antagonists, and inhibitors of other key platelet targets.
These agents aim to overcome the limitations of current therapies by offering improved efficacy and/or safety profiles.
Clinical evaluation is ongoing for these promising new drugs.

Conclusions:

Substantial progress in understanding platelet activation has led to the development of promising novel antiplatelet agents.
These new therapies have the potential to improve outcomes for patients with atherothrombotic disease.
Further clinical evaluation is essential to establish the role of these agents in preventing and treating arterial thrombosis.